Last reviewed · How we verify

NCT06986564

Evaluation of Decision Compatibility Between a Multidisciplinary Cancer Board and ChatGPT-4O

Completed Last updated 23 May 2025
What this trial tests

trial in Cancer in 100 participants. Completed in 1 May 2025.

Timeline
1 November 2024
Primary endpoint
30 January 2025
1 May 2025

Quick facts

Lead sponsorSebahattin Celik MD
StatusCompleted
Study typeOBSERVATIONAL
Enrollment100
Start date1 November 2024
Primary completion30 January 2025
Estimated completion1 May 2025
Sites1 location across Turkey (Türkiye)

Conditions studied

Sponsor

Sebahattin Celik MD

Who can join

18 and older, any sex, with Cancer or Artificial Intelligence. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study aims to compare the decisions of a multidisciplinary cancer board at Van research and educational Hospital with those generated by ChatGPT-4O. Patient data, including age, gender, comorbidities, clinical findings, laboratory results, radiology, and pathology reports, will be collected and recorded in patient files. These records will then be converted into a textual format appropriate for input into the ChatGPT-4O model. Statistical analyses will be conducted to assess the level of agreement between the board's decisions and those of ChatGPT-4O, providing insights into their compatibility and potential utility in clinical practice.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Cancer

Currently open trials in the same condition.

Other Sebahattin Celik MD trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06986564.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing